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Abstract 
Background 
This study explored the psychometric properties (internal consistency, construct validity, 
discriminative ability) of the Juniper Mini Asthma Quality of Life Questionnaire (Mini 
AQLQ-J) and the Sydney Asthma Quality of Life Questionnaire (AQLQ-S). 
Methods 
One hundred fourty-six adults (18–45 years) with asthma requiring regular inhaled 
corticosteroids were recruited to a trial of written emotional disclosure. Correlational analyses 
were performed to understand the relationship of the two measures with each other, with 
symptoms, lung function, asthma control, asthma bother and generic quality of life. Median 
quality of life scores were compared according to gender, health care usage and levels of 
asthma severity. 
Results 
AQLQ-J and AQLQ-S total scores correlated strongly with each other (rho = −0.80) and 
moderately with the EuroQol Current Health Status Scale (AQLQ-J: rho = 0.35; AQLQ-S: 
rho = −0.40). Domain score correlations between AQLQ-J and AQLQ-S were mostly 
moderate (0.5 < rho < 0.8). 
Both QoL measures were significantly correlated with symptom score. Correlations with the 
symptom score asthma module (AQLQ-J: rho = −0.69; AQLQ-S: rho = 0.50) were stronger 
compared with the total symptom score and the symptom score rhinitis module (AQLQ-J: 
rho = −0.41; AQLQ-S: rho = 0.31). 
Neither QoL measure was significantly correlated with FEV1% predicted at the total or the 
domain level. 
Total scores of both measures were significantly correlated with subjective asthma control 
(AQLQ-J: rho = 0.68; AQLQ-S: rho = −0.61) and asthma bother (AQLQ-J: rho = −0.73; 
AQLQ-M: rho = 0.73). 
Total AQLQ-J score and total AQLQ-S score were significantly associated with perceived 
asthma severity (AQLQ-J: p = 0.004, AQLQ-S: p = 0.002) and having visited a GP in the 
past four months (AQLQ-J: p = 0.003, AQLQ-S: p = 0.002) 
Conclusions 
This study provides further evidence for the validity of the AQLQ-J and the AQLQ-S in a 
British population of adult patients with asthma managed in primary care. Correlations with 
lung function parameters were weak or absent. Correlations with generic quality of life were 
moderate, those with asthma symptoms, asthma control and asthma bother were strong. Both 
measures are able to discriminate between levels of asthma severity and health care usage. 
Background 
Patient reported outcome measures (PROMs) have gained importance in clinical trials, 
epidemiological surveys, audit and clinical practice. „PROM‟ is an umbrella term proposed 
by the US Food and Drug Administration (FDA) denoting the “measurement of any aspect of 
a patient‟s health status that comes directly from the patient (i.e. without the interpretation of 
the patient‟s responses by a physician or anyone else)” [1]. PROMs are a means of 
quantifying qualitative information requiring careful consideration in their development [2]. 
Health-related quality of life (HrQoL) is among the most important patient assessed health 
outcomes but is also referred to as health status, perceived health or simply „quality of life‟ 
[3]. No single concept has been universally adopted [1,4,5]. 
For adults with asthma, a variety of health related quality of life (HrQoL) measures are in 
use. A recent review identified six commonly used questionnaires and concluded that the 
measures differ substantially in a number of aspects (conceptual and measurement model, 
reliability, validity, interpretability, burden of completion, administration format, validated 
translations) [6]. Among these measures were the Sydney Asthma Quality of Life 
Questionnaire (AQLQ-S) [7,8] and the Juniper Asthma Quality of Life (AQLQ-J) 
Questionnaire [9,10]. 
The validation of a PROM is a continuous process as evidence needs to accumulate to 
increase the confidence in the reliability and validity of a measure. Estimates of reliability 
and validity are always sample-dependent (i.e. the coefficients obtained are expected to vary 
from sample to sample) [11], hence it is important to publish the respective coefficients so a 
clear picture of the performance of the questionnaires can be built up. We therefore studied 
the internal consistency and validity (construct validity and discriminative ability) of the 
AQLQ-S and the AQLQ-J (mini version).. 
Furthermore, few studies have been conducted which look at quality of life measures used for 
asthma in a comparative manner [12-14]. This is important to get a sense of the relative 
validity and conceptual structure of PROMs which claim to measure the same thing. As a 
secondary objective, we therefore compared the psychometric properties of the AQLQ-S and 
the Mini AQLQ-J. 
Methods 
First, the study population was characterised by means of descriptive statistics. Second, 
measures of internal consistency were calculated for the mini AQLQ-J and the AQLQ-S. 
Third, we investigated how the two measures related to: 
• each other 
• symptom score 
• lung function 
• asthma control 
• asthma bother 
• generic quality of life 
Finally, the discriminative ability of the two asthma-specific measures with respect to age, 
gender, health care utilisation (GP visits) and perceived asthma severity was examined. 
Data source 
Data were drawn from the baseline assessment of a double blind randomised controlled trial 
(RCT) investigating the effects of a written emotional disclosure (WED) intervention in adult 
patients with asthma in the UK. One hundred fourty-six adults (18–45 years) with a diagnosis 
of asthma requiring regular inhaled corticosteroids were recruited into this trial. Participants 
were allocated to receive either WED or non-emotional writing instructions and asked to 
write for 20 minutes over three consecutive days. Spirometry, health care utilisation, asthma-
specific and generic quality of life, rhinoconjunctivitis and asthma symptoms, subjective 
asthma control and asthma bother were documented. The participants‟ lung function was 
measured using a Vitalograph Micro spriometer. The remaining constructs were assessed 
using self-administered questionnaires (the questionnaires were sent to participants and 
completed prior to the visit by the researcher, i.e. prior to the administration of the 
intervention). The questionnaires were administered in the same order each time: 
Rhinoconjuntivitis and Asthma Symptom Score, Asthma Control Test, Mini AQLQ-J, 
AQLQ-S, Profile of Mood States, EuroQoL Current Health status, Significant Other Scale 
and Asthma Bother Profile. It must be noted that we used the mini version of the AQLQ-J 
because this and not the original version was included in the randomised controlled trial 
(RCT) from which the data was drawn. The Profile of Mood States and the Significant Other 
Scale were not considered for this paper. 
The trial was registered with www.controlled-trials.com, registration number 
ISRCTN82986307. Ethical approval was obtained from the Brighton and Mid Sussex 
Research Ethics Committee (reference number 04/Q1907/91). 
Quality of life measures 
The AQLQ-J was developed in Canada and comprises 32 items in four domains with a two-
week recall period [9,10]. Higher ratings denote less impairment (better quality of life). Later, 
a shorter and simpler questionnaire with 15 items in the same domains was developed (Mini 
AQLQ-J) [15]. There are five items in the domain „Symptoms‟, four items in the domain 
„Activity Limitations‟, three items in the domain „Emotional Function‟ and three items in the 
domain „Environmental Stimuli‟. Higher scores indicate better quality of life. This 
questionnaire showed good measurement properties, but they were not quite as strong as for 
the original AQLQ-J [15]. The minimal important difference of quality of life score per item 
has been reported to be very close to 0.5 (range 0.42-0.58) for the original AQLQ-J [16]. 
The AQLQ-S was developed in Australia and comprises 20 items with a four-week recall 
period [7,8]. Lower ratings indicate less impairment (better quality of life). Items are grouped 
into four domains (breathlessness: five items, mood: five items, social: seven items, concerns: 
three items). The content of the questionnaires is illustrated in Table 1. For the AQLQ-S, a 
minimal important difference has not been reported. 
Table 1 Number of items and content of the AQLQ-J and the AQLQ-S 
Domain Number 
of items 
Content 
AQLQ-J 
symptoms 
5 Feeling short of breath as a result of asthma, feeling bothered by 
coughing, experiencing a feeling of chest tightness or chest 
heaviness, having difficulty getting a good night‟s sleep as a result 
of asthma, experiencing a wheeze in the chest 
AQLQ-S 
breathlessness 
5 Having been troubled by episodes of shortness of breath, having 
been troubled by wheezing attacks, having been troubled by 
tightness in the chest, having been restricted in walking down the 
streets or level ground or doing light housework because of asthma, 
having been restricted in walking up hills or doing heavy 
housework because of asthma 
AQLQ-J 
environment 
3 Feeling bothered by or having to avoid dust in the environment, 
feeling bothered by or having to avoid cigarette smoke in the 
environment, feeling bothered or having to avoid going outside 
because of weather or air pollution 
AQLQ-S 
concerns 
3 Having been worried about asthma shortening the life, having felt 
dependent on asthma sprays, having been worried about present or 
future life because of asthma 
AQLQ-J 
emotions 
3 Feeling frustrated as a result of asthma, feeling afraid of not having 
asthma medication available, feeling concerned about having 
asthma 
AQLQ-S mood 3 Having felt tired or a general lack of energy, having been unable to 
sleep at night, having felt sad or depressed, having felt frustrated 
with oneself, having felt anxious, under tension or stressed 
AQLQ-J 
activities 
4 Having been limited in doing strenuous activities (such as hurrying, 
exercising, running up chairs, sports) as a result of asthma; having 
been limited in doing moderate activities (such as walking, 
housework, gardening, shopping, climbing stairs) as a result of 
asthma, having been limited in doing social activities (such as 
talking, playing with pets/children, visiting friends/relatives), 
having been limited in doing work-related activities* (tasks you 
have to do at work) 
AQLQ-S social 7 Having felt that asthma is preventing one from achieving what one 
wants in life, asthma having interfered with one‟s social life, 
having been limited in going to certain places because they are bad 
for one‟s asthma, having been limited in going to certain places 
because of having been afraid if getting an asthma attack and not 
being able to get help, having felt generally restricted, having been 
restricted in the sports, hobbies, or other recreations one can engage 
in because of one‟s asthma, having felt asthma is controlling one‟s 
life 
*these should be activities which one has to do most days if not employed or self-employed 
The EuroQoL Current Health Status Scale (CHS) is a generic, preference-based measure of 
health status and consists of five items (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression) [17]. Higher scores indicate better quality of life. 
Lung function measurement 
The following parameters were measured in spirometry: forced vital capacity (FVC) in litres 
[l], forced expiratory volume in one second (FEV1) in litres [l], peak expiratory flow (PEF) 
in litres per minute [l/min]. The European Coal and Steel Community (ECSC) prediction 
equations were used to calculate what participant‟s optimum lung function should be based 
on age, height and gender [18,19]. This reading was used with FEV1 scores to determine 
FEV1% predicted scores. 
Rhinoconjunctivitis and Asthma symptom score 
The Rhinoconjunctivitis and Asthma Symptom Score has 21 items which are rated on a five 
point Likert scale [20,21]. Patients are asked how much they have been disturbed by 
symptoms during the last week. The rhinitis module of the score asks about symptoms of 
irritation, congestion and discharge in the eyes, the nose and the sinuses. The asthma module 
asks about daytime and nighttime symptoms of cough, wheeze, sputum production and 
shortness of breath. Asthma Control Test (ACT) 
The Asthma Control Test (ACT) consists of five questions pertaining to the past 4 weeks 
[22,23]. The brief questionnaire assesses asthma symptoms (daytime and nocturnal), use of 
rescue medications, and the effect of asthma on daily functioning. The total score is obtained 
by summing the scores for each item and ranges from 5 (poor control of asthma) to 25 
(complete control of asthma). 
Asthma Bother Profile (ABP) 
The Asthma Bother Profile (ABP) is a 15 item measure of asthma distress [24]. Patients are 
asked how much their asthma bothers them in the different areas of their life and they are 
given six response options (no bother, minor irritation, slight bother, moderate bother, a lot of 
bother, makes my life a misery) and one „not applicable‟ option. Higher scores indicate 
greater distress. 
Statistical analysis 
To describe the characteristics of the sample, counts and percent were calculated for 
categorical variables and means with standard deviations (SD) were calculated for continuous 
variables. 
In order to analyse the distribution of domain and total scores for the two asthma-specific 
quality of life measures mean, median, standard deviation (SD), percentage of participants 
with missing items, observed range, the percentage of participants with the worst possible 
score („floor‟) and percentage of participants with the best possible score („ceiling‟) were 
calculated. Standardized Cronbach alpha coefficients were computed as a measure of internal 
consistency [25]. 
Correlational analyses were performed to analyse the relationship between scores where 
appropriate. Spearman rank-order correlations, nonparametric measures of association based 
on the ranks of the data values, were calculated because the scores of the measures of interest 
(AQLQ-J and AQLQ-S) were not normally distributed. 
In order to analyse the relationship between the domain and total scores of the AQLQ-J and 
the AQLQ-S, a correlation matrix was computed. Correlations were considered as absent if 
rho < 0.20, poor if rho = 0.20-0.34, moderate if rho = 0.35-0.50 and strong if rho > 0.50 [26]. 
In order to compare scores between categories (gender, GP visits, perceived severity), non-
parametric tests were used (Wilcoxon rank sum two sample test for comparison between two 
groups and Kruskal-Wallis test for comparison between more than two groups). Missing data 
in the questionnaires were dealt with by imputing mean values where more than half of the 
responses to a subscale were present. 
All analyses were performed using SAS 9.2 for Windows. 
Results 
Patient characteristics 
One hundred fourty-six people with asthma (average disease duration: 21.4 years (SD: 11.5 
years)), aged 18–45 years and with a mean age of 36.1 years (SD: 7.0 years), participated in 
the study. Most of the participants were female (76.7%), in employment (82.2%) and of white 
ethnicity (97.3%). Their asthma was perceived as mild by 48.0%, as moderate by 45.9% and 
as severe by 3.4%. About one quarter (25.3%) of all patients reported consulting their general 
practitioner because of their asthma during the past four months (excluding asthma review 
appointments), 3.4% reported they had visited Accident & Emergency (A&E) because of 
their asthma during the past four months but none reported having been admitted to hospital 
in the same time period. 
The distribution of the questionnaire scores is displayed in Table 2. The mean AQLQ-J score 
was 5.4 (SD 1.0, minimum 1.7, maximum 7.0), the mean AQLQ-S was 0.8 (SD 0.6, 
minimum 0.1, maximum 3.4). About one quarter of the responses in the „activity limitation‟ 
domain of the AQLQ-J and the „social‟ domain of the AQLQ-S were the best possible scores 
(ceiling effect). 
Table 2 Distribution of scores and internal consistency of AQLQ-J and AQLQ-S 
 AQLQ-J AQLQ-S 
 Symptoms Environmental 
Stimuli 
Emotional 
Function 
Activity 
Limitation 
Total Breathlessness Mood Social Concerns Total 
Items [n] 5 3 3 4 15 5 5 7 3 20 
Mean 5.06 5.38 5.18 5.97 5.39 0.83 0.99 0.52 0.76 0.80 
Median 5.20 5.67 5.33 6.25 5.60 0.60 0.80 0.29 0.57 0.70 
SD 1.15 1.24 1.48 1.12 1.04 0.60 0.76 0.68 0.66 0.58 
Participants 
with missing 
items [%] 
4.79 4.79 5.48 5.48 6.16 5.48 5.48 4.79 5.48 5.48 
Theoretical 
range 
1-7 1-7 1-7 1-7 1-7 0-4 0-4 0-4 0-4 0-4 
Observed range 1.80-7.00 1.33-7.00 1.00-7.00 1.50-7.00 1.67-7.00 0-3.0 0-3.80 0-4.0 0-3.57 0.05-3.35 
„Floor‟ [%]* 0 0 1.45 0 0 0 0 0 0 0 
„Ceiling‟ [%]** 1.44 10.79 10.87 25.36 0.73 5.80 10.90 26.62 12.32 0 
Cronbach‟s 
alpha 
0.85 (N = 
139) 
0.61 (N = 139) 0.82 (N = 
138) 
0.89 (N = 
138) 
0.92 (N = 
137) 
0.83 (N = 138) 0.85 (N = 
138) 
0.91 (N = 
139) 
0.77 (N = 
139) 
0.93 (N = 
138) 
*Percentage of participants with worst possible score 
**Percentage of patients with best possible score 
Mean rhinoconjunctivitis and asthma symptom score was 45.2 (SD: 13.9, median: 44.5, 
range: 20.0-89.0, N = 136). For the asthma module, mean symptom score was 20.4 (SD: 7.6, 
median: 19.0, range: 9.0 - 42.0, N = 137) and for the rhinitis module, mean symptom score 
was 24.8 (SD: 8.1, median: 25.0, range: 11.0-48.0, N = 136). 
The following spirometry results were observed (N = 145): mean FVC was 3.72 l (SD 1.03, 
range: 1.37-7.35), mean FEV1 was 2.82 l (SD 0.77, range: 0.74-4.95), mean FEV1, % 
predicted was 87.5% (SD: 20.5, range: 24.8 - 167.3) and mean PEF was 427.4 l/min (SD: 
132.2, range: 117.0-847.0). 
Internal consistency 
Cronbach‟s alpha values for the total and the domain scores of both QoL measures are also 
displayed in Table 2. 
For the subscales of the AQLQ-J, all Cronbach‟s alpha values were > = 0.61 and for the 
subscales of the AQLQ-S, all Cronbach‟s alpha values were >  = 0.83. Cronbach‟s alpha was 
0.92 for the total AQLQ-J score and 0.93 for the total AQLQ-S score. 
Correlation of AQLQ-J and AQLQ-S 
A correlation matrix of the two measures is shown in Table 3. The total scores of the AQLQ-
J and AQLQ-S correlated strongly with each other (rho = −0.80, p < 0.0001). The domain 
scores of the AQLQ-J and AQLQ-S showed weaker, but still strong (0.5 < = rho < = 0.8) 
correlations with each other. The only exception was the „mood‟ domain of the AQLQ-S 
which correlated moderately (rho <0.5) with the „environmental stimuli‟, the „emotional 
function‟ and the „activity limitation‟ domain of the AQLQ-J. 
Table 3 Relationship of domain and total scores of AQLQ-J and AQLQ-S (correlation matrix) 
 AQLQ-J AQLQ-S 
 Symptoms Environmental 
Stimuli 
Emotional 
Function 
Activity 
Limitation 
Total Breathlessness Mood Social Concerns Total 
AQLQ-J           
Symptoms - 0.54 0.68 0.60 0.90      
Environmental 
Stimuli 
 - 0.52 0.47 0.73      
Emotional Function  0.52 -  0.82      
Activity Limitation  0.47 0.51 - 0.78      
Total     -      
AQLQ-S           
Breathlessness -0.74 -0.42 -0.54 -0.61 -0.72 -     
Mood -0.57 -0.36 -0.46 -0.42 -0.58 0.57 -    
Social -0.52 -0.54 -0.53 -0.70 -0.68 0.56 0.41 -   
Concerns -0.59 -0.45 -0.65 -0.53 -0.68 0.59 0.61 0.68 -  
Total -0.73 -0.52 -0.66 -0.66 -0.80 0.81 0.80 0.76 0.88  
Spearman‟s rank correlation coefficients, all correlation coefficients showed p values < 0.0001 
Correlations between AQLQ-J and AQLQ-S scores are negative because the respective scores run in opposite directions 
Correlation of AQLQ-J and AQLQ-S with Rhinoconjunctivitis and Asthma 
Symptom Score 
Both QoL measures were significantly correlated with the Rhinoconjunctivitis and Asthma 
Symptom Score, but the correlation of the AQLQ-J with the symptom score was stronger 
(rho = −0.62, p < 0.0001, N = 134) compared with the correlation of the AQLQ-S (rho = 
0.46, p < 0.0001, N = 135). For both QoL measures, correlations with the symptom score 
asthma module (AQLQ-J: rho = −0.69, p < 0.0001, N = 135; AQLQ-S: rho = 0.50, p < 
0.0001, N = 136) were stronger compared with the total symptom score and the symptom 
score rhinitis module (AQLQ-J: rho = −0.41, p < 0.0001, N = 134; AQLQ-S: rho = 0.31, p = 
0.0002, N = 135). 
Correlation of AQLQ-J and AQLQ-S with lung function 
As shown in Table 4, the AQLQ-J total score and all domain scores except „emotional 
function‟ were significantly correlated with FVC, but only the association with environmental 
stimuli was of moderate strength. Regarding the AQLQ-S, a significant, but weak correlation 
with FVC was found for the „breathlessness‟ domain. The AQLQ-J total score and the 
domains „environmental stimuli‟ as well as „activity limitation‟ showed significant, but weak 
correlations with FEV1 and PEF. 
Table 4 Relationship of spirometry parameters with domain and total scores of AQLQ-J and AQLQ-S 
 AQLQ-J AQLQ-S 
 Symptoms 
(N = 138) 
Environment
al Stimuli (N 
= 138) 
Emotional 
Function 
(N = 137) 
Activity 
Limitation 
(N = 137) 
Total 
(N = 136) 
Breathless
ness 
(N = 137) 
Mood 
(N = 137) 
Social 
(N = 138) 
Concerns 
(N = 137) 
Total 
(N = 137) 
FVC 0.24 (p = 
0.005) 
0.36  
(p<0.0001) 
0.17 (p = 
0.05) 
0.33 
(p<0.0001
) 
0.33 
(p<0.0001
) 
-0.22  
(p = 0.01) 
-0.12 
(p = 0.15) 
-0.16 
(p = 0.05) 
-0.11 
(p = 0.19) 
-0.17  
(p = 0.05) 
FEV1 0.15 (p = 
0.07) 
0.20 
(p = 0.02) 
0.08 (p = 
0.38) 
0.23 (p = 
0.007) 
0.20 (p = 
0.02) 
-0.16 
(p = 0.07) 
-0.05 
(p = 0.56) 
-0.07 
(p = 0.39) 
-0.06 
(p = 0.50) 
-0.09 
(p = 0.31) 
PEF 0.13 (p = 
0.13) 
0.26  
(p = 0.002) 
0.12 (p = 
0.17) 
0.32 (p = 
0.0001) 
0.24 (p = 
0.006) 
-0.18 
(p = 0.04) 
-0.09 
(p = 0.32) 
-0.22 
(p = 0.01) 
-0.09 
(p = 0.32) 
-0.14 
(p = 0.09) 
FEV1, 
% 
predicte
d 
0.15 (p = 
0.08) 
0.09  
(p = 0.32) 
0.10 
(p = 0.25) 
0.17 (p = 
0.05) 
0.16 (p = 
0.06) 
-0.17 
(p = 0.05) 
-0.01 
(p = 0.88) 
-0.09 
(0.31) 
-0.10 
(p = 0.26) 
 
-0.09 
(p = 0.29) 
Spearman‟s rank correlation coefficients 
Neither the total score nor any domain score of the AQLQ-S were significantly correlated 
with FEV1. There were, however, significant correlations of the AQLQ-S domains 
„breathlessness‟ and „social‟ with PEF. The correlation with „breathlessness‟ qualified as 
absent, while the correlation with „social‟ classified as weak. No significant correlation of 
either QoL measure at total or domain level was observed with FEV1, % predicted. 
Correlation of AQLQ-J and AQLQ-S with asthma control 
Both AQLQ-J total score (rho = 0.68, p < 0.0001, N = 136) and AQLQ-S total score (rho = 
−0.61, p < 0.0001, N = 137) were significantly correlated with asthma control. 
Correlation of AQLQ-J and AQLQ-S with Asthma Bother Profile (ABP) 
Both QoL measures correlated significantly with the ABP to the same degree (AQLQ-J: rho 
= −0.73, p < 0.0001, N = 130; AQLQ-S: rho = 0.73, p < 0.0001, N = 131). 
Correlation of AQLQ-J and AQLQ-S with EuroQoL current health status 
(CHS) 
Both AQLQ-J (rho = 0.35, p < 0.0001, N = 134) and the AQLQ-S (rho = −0.40, p < 0.0001, 
N = 135) correlated significantly with the EuroQoL Current Health Status Scale (CHS). 
Relationship of AQLQ-J and AQLQ-S to patient characteristics (age, gender, 
GP visits, perceived asthma severity) 
Neither measure correlated with age (rho = 0.01, p = 0.92, N = 137 for the AQLQ-J and rho 
= −0.03, p = 0.77, N = 138 for the AQLQ-S). As shown in Table 5, there was no significant 
difference between male and female in total AQLQ-J scores, but a significantly better QoL 
score was observed in the male group for the domains „environmental stimuli‟ and „activity 
limitation‟. No significant difference between male and female was observed for the AQLQ-
S total and in the domains. 
Table 5 Median score (interquartile range) of AQLQ-J and AQLQ-S according to patient characteristics 
 AQLQ-J AQLQ-S 
 Symptoms Environme
ntal 
Stimuli 
Emotional 
Function 
Activity 
Limitation 
Total Breathless
ness 
Mood Social Concerns Total 
Gender           
Female 5.20 
(4.20-
6.00) 
N = 105 
5.67 
(4.67-
6.00) 
N = 105 
5.33 
(4.00-
6.33) 
N = 105 
6.25 
(5.25-
6.75) 
N = 104 
5.50 
(4.57-
6.07) 
N = 104 
0.80 (0.40-
1.20) 
N = 104 
0.80 (0.40-
1.40) 
N = 104 
0.29 (0.00-
0.86) 
N = 105 
0.57 (0.29-
1.14) 
N = 104 
0.70 (0.35-
1.10) 
N = 104 
Male 5.10 
(4.60-
6.00) 
N = 34 
6.00 
(5.33-
7.00) 
N = 34 
5.67 
(4.33-
6.33) 
N = 33 
6.63 
(5.75-
7.00) 
N = 34 
5.93 
(5.27-
6.20) 
N = 33 
0.60  
(0.40-
1.00) 
N = 34 
0.90 (0.40-
1.40) 
N = 34 
0.14 (0.00-
0.71) 
N = 34 
0.64 (0.29-
1.00) 
N = 34 
0.63 (0.45-
0.95) 
N = 34 
P value* 0.58 0.003 0.61 0.03 0.10 0.48 0.70 0.39 0.74 0.69 
 
Health 
care usage 
(GP visit) 
during the 
past four 
months 
          
Yes 4.20  
(3.60-
5.20) 
N = 35 
5.33  
(4.00-
6.00) 
N = 35 
5.00  
(4.00-
6.33) 
N = 35 
6.00  
(4.25-
6.75) 
N = 35 
4.93 (4.40-
5.93) 
N = 35 
1.00  
(0.60-
1.60) 
N = 35 
1.20 (0.80-
1.80) 
N = 35 
0.29 (0.00-
1.29) 
N = 35 
0.86 (0.43-
1.43) 
N = 35 
0.90 (0.55-
1.55) 
N = 35 
No 5.40  
(4.60-
6.10) 
N = 104 
5.67  
(4.67-
6.33) 
N = 104 
5.67  
(4.33-
6.67) 
N = 103 
6.25  
(5.75-
7.00) 
N = 103 
5.77 (5.13-
6.20) 
N = 102 
0.60  
(0.40-
1.00) 
N = 103 
0.80  
(0.40-
1.20) 
N = 103 
0.29 (0.07-
0.71) 
N = 104 
0.57 (0.29-
1.00) 
N = 103 
0.55 (0.35-
0.95) 
N = 103 
P value* 0.0009 0.05 0.09 0.04 0.003 0.002 0.0003 0.51 0.01 0.002 
           
Perceived 
asthma 
severity 
          
No 
symptoms 
6.10  
(5.40-
6.20) 
N = 4 
6.00  
(5.50-
6.50) 
N = 4 
6.00 
(5.50-
6.67) 
N = 4 
6.88  
(6.38-
7.00) 
N = 4 
6.27 (5.73-
6.53) 
N = 4 
0.30  
(0.20-
0.50) 
        N = 4 
0.40 (0.10-
0.70) 
N = 4 
0.14 (0.07-
0.50) 
N = 4 
0.00 (0.00-
0.43) 
N = 4 
0.23 (0.15-
0.48) 
N = 4 
Mild 5.40  
(4.60-
6.20) 
N = 67 
5.67  
(4.67-
6.00) 
N = 67 
6.00  
(4.67-
6.67) 
N = 67 
6.50  
(6.00-
7.00) 
N = 66 
5.80 (5.20-
6.33) 
N = 66 
0.60  
(0.40-
0.80) 
N = 66 
0.80 (0.40-
1.20) 
N = 66 
0.14 (0.00-
0.71) 
N = 67 
0.43 (0.29-
1.00) 
N = 66 
0.53 (0.35-
0.90) 
N = 66 
Moderate 5.00  
(3.90-
5.80) 
N = 64 
5.67  
(4.67-
6.33) 
N = 64 
5.00  
(4.00-
6.00) 
N = 63 
6.25  
(5.13-
6.75) 
N = 64 
5.33 (4.53-
5.93) 
N = 63 
0.80  
(0.60-
1.40) 
N = 64 
0.98 (0.50-
1.40) 
N = 64 
0.29 (0.00-
0.86) 
N = 64 
0.71 (0.43-
1.21) 
N = 64 
0.73 (0.45-
1.28) 
N = 64 
Severe 3.50  
(2.60-
4.10) 
N = 4 
4.17  
(2.67-
5.33) 
N = 4 
3.50  
(2.17-
5.33) 
N = 4 
4.50  
(3.63-
5.88) 
N = 4 
4.20 (2.93-
4.93) 
N = 4 
1.70 (1.30-
2.20) 
N = 4 
1.70 (1.60-
2.80) 
N = 4 
1.38 (0.29-
2.93) 
N = 4 
1.43 (0.71-
2.79) 
N = 4 
1.58 (1.03-
2.65) 
N = 4 
P value** 0.003 0.28 0.01 0.05 0.004 0.0002 0.007 0.29 0.008 0.002 
*Wilcoxon rank sum two sample test (normal approximation, including continuity correction) 
**Kruskal-Wallis test 
Scores were significantly worse for those patients who reported having visited their GP 
during the past four months for the AQLQ-J total and the „symptom‟ and „activity limitation‟ 
domains. They were also significantly worse for the AQLQ-S total as well as the 
„breathlessness‟, „mood‟ and „concerns‟ domains. 
The relationship between median quality of life scores and perceived asthma severity was 
significant for the „symptoms‟ and „emotional function‟ domain scores of the AQLQ-J as 
well as the total AQLQ-J score. The relationship between median quality of life scores and 
perceived asthma severity was also significant for the „breathlessness‟, „mood‟, „concerns‟ 
domains and the total score of the AQLQ-S. 
Discussion 
Overall, we observed mild quality of life impairment in our sample of adult patients with 
asthma recruited in Southern England, as measured by the mini version of the Juniper 
Asthma Quality of Life Questionnaire (AQLQ-J) and the Marks Asthma Quality of Life 
Questionnaire (AQLQ-S). Like in a previous Dutch study [13], this may be explained by the 
fact that all patients were recruited through primary care. 
Missing item-level data were imputed as the mean of at least 50% of the subscale items. 
Ordinarily this might be expected to reduce the precision of calculated statistics. However, in 
this context imputation of values from at least 50% of subscale items is acceptable, since the 
subscale items were highly correlated with each other (as should be expected for items on a 
common subscale). Hence it was reasonable to infer a given missing item value from the 
mean value of the completed items. In fact, the highest percentage of missing data among all 
the scales used was 9.6% for the Asthma Bother Profile. 
We found acceptable internal consistency (α > 0.7) for both asthma-specific quality of life 
measures at total and domain level, except for the „environmental stimuli‟ domain of the 
AQLQ-J. 
Both measures correlated strongly with each other at the total score level. This was also true 
for most domain-domain correlations. Similarly strong domain-domain and domain-total as 
well as total-total correlations were found in a Spanish study which compared the 
performance of the full version of the AQLQ-J and the St George‟s Respiratory 
Questionnaire (SGRQ) [27]. 
Correlations with the symptom score, particularly the asthma module of the symptom score, 
were strong for the AQLQ-J and moderate for the AQLQ-S. 
The strength of the correlation of the AQLQ-J (rho = 0.69) with asthma symptoms we found 
was comparable to that found in the Dutch study (rho = 0.65) [13]. Taking the perspective of 
van der Molen et al. [13] this may be interpreted as evidence for (cross-sectional) construct 
validity, although we have taken the stance before that not symptoms per se, but the impact of 
symptoms is influencing asthma-specific quality of life [6]. Hence, the strong correlation of 
the AQLQ-J with the symptom score may raise the question of overlap between the symptom 
score construct and the quality of life construct as operationalized in the AQLQ-J. 
The stronger correlation of the AQLQ-J compared to the AQLQ-S with the symptom score 
seems plausible in the light of the fact that the AQLQ-J has more symptom-related items 
compared to the AQLQ-S. 
The finding that correlations of both measures (at total and domain level) with lung function 
measures were weak, if not absent, was expected. It corroborates previous findings [13,14]. 
The AQLQ-J showed more and stronger correlations with lung function measures. This was 
expected because the AQLQ-J has more symptom-based items. The findings for lung 
function contrasted with the strong correlations found for asthma bother and asthma control. 
Taking the moderate strength of the correlations with generic quality of life into account, we 
interpret the findings from these correlational analyses as supporting evidence for construct 
validity of both measures. 
The relationships of the AQLQ-J and AQLQ-S with health care utilization as measured by 
GP visits and with perceived asthma severity were as expected and support the discriminative 
ability of both measures. The observed gender difference is less clear. There are few studies 
looking into gender differences in asthma-specific quality of life. A very recent study from 
India found that women reported poorer quality of life, especially in the symptoms and 
emotional domains of the AQLQ [28]. The findings point in a similar direction to our 
findings, however we found significant differences in the “environmental stimuli” and 
“activity limitation” domains. 
Conclusions 
This study provides evidence for the validity of the mini AQLQ-J and the AQLQ-S in a 
British population of adults with asthma who are managed in primary care. The correlations 
with lung function and symptoms were different for the two measures and stronger for the 
mini AQLQ-J compared to the AQLQ-S, reflecting partly the different content of the 
questionnaires. Both the mini AQLQ-J and the AQLQ-S are able to discriminate between 
patients with differing levels of asthma severity. 
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